3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Intraepithelial Lesions
2
Uterine Cervical Dysplasia
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Melanoma
1
HIV Seropositivity
1
Interventions
Prednisone
112
Docetaxel
87
Leuprolide
79
enzalutamide
72
Abiraterone Acetate
67
bicalutamide
53
Goserelin
50
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
42
Radiotherapy
39
abiraterone
28
Magnetic Resonance Spectroscopy
27
Gonadotropin-Releasing Hormone
24
gallium 68 PSMA-11
23
apalutamide
22
Androgen Antagonists
22
luprolide acetate gel depot
21
sipuleucel-T
20
Radiosurgery
20
Triptorelin Pamoate
18
cabazitaxel
17
cabozantinib
16
Radiotherapy, Intensity-Modulated
16
Flutamide
16
pembrolizumab
15
radium Ra 223 dichloride
14
Prednisolone
14
Nivolumab
14
Dutasteride
14
Dexamethasone
14
Radiation
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Prostatic Neoplasms
×
Electroporation
×
Clear all
NCT04972097
2026-06-02
PRESERVE
Angiodynamics, Inc.
Phase NA
Completed
121 enrolled
19 charts